AADAT Knockout cell line (A-375)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

AADAT (aminoadipate aminotransferase) encodes a mitochondrial aminotransferase involved in amino acid metabolism. The enzyme catalyzes transamination of alpha-aminoadipic acid, a step in the saccharopine pathway of L-lysine catabolism, and also catalyzes conversion of kynurenine to kynurenic acid, a metabolite with neuroactive properties. Through these activities, AADAT contributes to lysine and tryptophan metabolism and may influence cellular levels of metabolites involved in metabolic and neuronal processes.

The A375 cell line is a highly characterized human malignant melanoma model derived from a 54-year-old female patient. As referenced in image_2f51f1.png, this adherent cell line demonstrates robust translational performance in in vivo xenograft studies, reliably producing rapidly growing amelanotic melanomas when inoculated into anti-thymocyte serum-treated NIH Swiss mice. Serving as a globally recognized preclinical oncology platform, it is extensively utilized for investigating melanoma disease progression, executing high-throughput screening of novel therapeutics, and studying targeted signaling pathways in skin cancers.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.